Sirius Therapeutics Reports Promising Phase I Data for Next-Gen Anticoagulant
Sirius Therapeutics has announced promising preliminary results from its Phase 1 first-in-human clinical trial of SRSD107, a next-generation siRNA therapeutic under development for the prevention and treatment of thromboembolic disorders.…
Health Canada Approves Celltrion’s Omlyclo (CT-P39), Canada’s First Omalizumab Biosimilar
Celltrion has announced that Health Canada has approved Omlyclo™, the first and only biosimilar referencing Xolair® (omalizumab) in Canada. Omlyclo™ is now authorized for the treatment of adults and adolescents…
SK Pharmteco Combines Leading Brands to Establish a Global CDMO Powerhouse
SK pharmteco, a global leader in contract development, manufacturing, and analytical testing services for the pharmaceutical and cell & gene therapy industries, has announced a groundbreaking brand unification initiative. This…
Crown Bioscience Receives 2024 Fierce CRO Award for Outstanding Client Service and Partnership
Crown Bioscience, a leading global contract research organization (CRO) based in the United States and a part of JSR Life Sciences and Japan’s JSR Corporation, has been awarded the prestigious…
City of Hope Experts Showcase Innovative Cancer Therapies at ASH Annual Conference
City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S., presented groundbreaking findings at the ASH Annual Conference in San Diego from…
Agilent’s PD-L1 IHC 28-8 pharmDx Companion Diagnostic Assay Earns European IVDR Certification
Agilent Technologies today announced the issuance of a Class C Companion Diagnostic (CDx) In Vitro Diagnostic Regulation (IVDR) certification for its PD-L1 IHC 28-8 pharmDx (Code SK005) assay. This diagnostic…
Friends of Traditional Medicine Set 2025 Action Agenda
On November 29, the Group of Friends of Traditional Medicine convened in Geneva to explore opportunities for joint action in 2025, fostering collaboration and coordination among WHO Member States. Ambassadors…
Bio-Techne Unveils ESR1 Mutation Monitoring Assay
Bio-Techne Corporation announced the launch of a highly sensitive ESR1 mutation monitoring assay through its Asuragen brand. This innovative assay is designed for research use and aims to detect ESR1…
SILAL and Bayer Strengthen Agricultural Partnership with MOU
Silal and Bayer have reinforced their commitment to agricultural innovation in the UAE with the signing of a comprehensive Memorandum of Understanding (MoU) at the World Agri-Tech Innovation Summit in…
Roche Highlights Columvi & Lunsumio Data at ASH 2024 for Lymphoma Treatment
Roche presented new and updated findings from its pioneering CD20xCD3 T-cell-engaging bispecific antibody program at the 66th American Society of Hematology (ASH) Annual Meeting, held from December 7-10, 2024. With…
Biogen Names Tim Power as Head of Investor Relations
Biogen has appointed Tim Power as Vice President and Head of Investor Relations, effective December 9, 2024. In this role, Mr. Power will report directly to Michael McDonnell, the company’s…
CARVYKTI Boosts MRD Negativity in Relapsed Multiple Myeloma
Legend Biotech Corporation a global leader in cell therapy, recently unveiled groundbreaking results from the Phase 3 CARTITUDE-4 clinical trial, further cementing the efficacy of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) in…